What are the latest funding news in the AI in drug discovery market? (July 2026)
Download our beautiful pitch about the AI in drug discovery market
In our AI in drug discovery market deck, you will find everything you need to understand the market
AI in drug discovery funding stayed active in spring 2026, with large platform rounds and smaller specialist seed deals moving at the same time.
The latest deals show investor interest in AI drug design engines, protein characterization, toxicology prediction, antibody discovery, and molecular AI infrastructure.
The market is still broad, but the strongest fundraising stories are tied to clear preclinical value, not generic life sciences AI.
And if you want to better understand this new industry, you can download our pitch covering the AI in drug discovery market.
Insights
- The 12 latest AI in drug discovery fundraises totaled about $2.5B, but Isomorphic Labs alone represented more than 80% of disclosed capital.
- Seed rounds were still common, with six of the 12 deals at seed stage, showing continued formation of specialized AI discovery startups.
- The market is moving beyond molecule generation, with fresh funding for protein characterization, toxicology, delivery design, and molecular AI infrastructure.
- China had two of the three largest deals, helped by Artivila Biopharma's Series A and METiS TechBio's Hong Kong IPO.
- Europe remained highly visible in early-stage AI drug discovery, with Helical, Generare, Ternary Therapeutics, and Antiverse all raising in March and April.
- Most funded companies in this list are not replacing pharma R&D teams, but giving them sharper tools for earlier preclinical decisions.
- AI biologics and antibody discovery stayed active, with 10x Science, Antiverse, and RyboDyn targeting hard-to-measure proteins, antibodies, and hidden cancer targets.
- Several funded companies combine AI with lab feedback, which suggests investors still prefer discovery platforms that can validate predictions experimentally.
As this chart shows, and as featured in our AI in drug discovery market deck, search interest in AI drug discovery has grown rapidly
Summary table of the latest funding deals in the AI in drug discovery market as of July 2026
We define the AI in drug discovery market as revenue from AI-enabled software and related services that materially support the identification and design of therapeutic candidates before human trials.
We include AI used for target identification and validation, hit and lead generation, lead optimization, de novo design, repurposing, and preclinical prediction or assessment, including ADMET and toxicology.
We exclude AI primarily used for clinical trial operations, regulatory submissions, manufacturing, pharmacovigilance, or commercial and enterprise analytics not directly tied to discovery and preclinical candidate selection.
You can also read our detailed analysis to understand how funding activity in the AI in drug discovery market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the AI in drug discovery market (we update this list every quarter) as well as our ranking of the most funded startups.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Tamarind Bio | 26 February 2026 | $13.6M | Series A plus additional funding | Molecular AI model infrastructure & simulation |
| Antiverse | 3 March 2026 | $9.3M | Series A | AI antibody discovery & biologics lead generation |
| Ternary Therapeutics | 16 March 2026 | ~$4.5M | Seed | AI molecular-glue design & targeted protein degradation |
| RyboDyn | 24 March 2026 | $10M | Seed initial close | AI target discovery & dark proteome mapping |
| Generare | 2 April 2026 | ~$23M | Series A | AI lead generation & natural-product discovery |
| DeepCyte | 9 April 2026 | $1.5M | Seed | Preclinical prediction & ADMET toxicology |
| Helical | 14 April 2026 | $10M | Seed | AI discovery infrastructure & virtual lab |
| 10x Science | 22 April 2026 | $4.8M | Seed | Preclinical biologics assessment & protein characterization |
| Fathom Therapeutics | 27 April 2026 | $47M | Series A | AI and physics small-molecule design |
| Isomorphic Labs | 12 May 2026 | $2,100M | Series B | De novo design & AI drug design engine |
| METiS TechBio | 13 May 2026 | ~$270M | IPO | AI drug delivery & formulation design |
| Artivila Biopharma | 25 June 2026 | $12.8M+ | Series A | AI drug discovery platform & multi-modality pipeline |
All the latest funding deals in the AI in drug discovery market as of July 2026
Artivila Biopharma raised over $12.8M in Series A funding in June 2026
When was it?
The deal was announced on 25 June 2026.
Who are they?
Artivila Biopharma is a Shenzhen-based biotech using AI to support small-molecule, biologics, and cell and gene therapy pipelines.
Geographical focus?
Artivila Biopharma is China-first, with international expansion plans.
Why do we include them in the AI in drug discovery market?
Artivila Biopharma fits because its platform uses AI across target discovery, molecular design, and preclinical candidate development.
What is the company stage?
Artivila Biopharma is a clinical-stage growth company with multiple programs and an AI-enabled R&D platform.
How much did they raise?
Artivila Biopharma raised more than $12.8M in this round.
What round is it?
The round was a Series A financing.
Why did they raise?
Artivila Biopharma raised to strengthen R&D platforms, advance clinical programs, support IND filings, and prepare for international expansion.
METiS TechBio raised about $270M through its Hong Kong IPO in May 2026
When was it?
The deal was announced on 13 May 2026.
Who are they?
METiS TechBio applies AI, molecular simulation, quantum chemistry, and screening to drug delivery and formulation design.
Geographical focus?
METiS TechBio focuses on China and Hong Kong, with R&D links in Beijing, Hangzhou, Hong Kong, and Cambridge, Massachusetts.
Why do we include them in the AI in drug discovery market?
METiS TechBio fits because its AI platforms support drug delivery, formulation design, and preclinical candidate-enabling technology.
What is the company stage?
METiS TechBio is a public growth-stage company with clinical-stage candidates and platform infrastructure.
How much did they raise?
METiS TechBio raised about $270M through the IPO.
What round is it?
The round was an IPO on the Hong Kong Stock Exchange.
Why did they raise?
METiS TechBio raised to expand AI infrastructure, scale nanomaterial platforms, and fund ongoing and planned clinical work.
This chart, featured in our AI in drug discovery market deck, compares the main business model options for AI drug discovery biotech companies
Isomorphic Labs raised $2.1B in Series B funding in May 2026
When was it?
The deal was announced on 12 May 2026.
Who are they?
Isomorphic Labs builds an AI-first drug design engine for small molecules, biologics, and antibody candidates.
Geographical focus?
Isomorphic Labs is London-headquartered and works with global biopharma partners.
Why do we include them in the AI in drug discovery market?
Isomorphic Labs fits because its IsoDDE platform supports de novo design, lead optimization, and AI drug design before trials.
What is the company stage?
Isomorphic Labs is a growth-stage company moving from discovery and preclinical work toward clinical translation.
How much did they raise?
Isomorphic Labs raised $2,100M in this round.
What round is it?
The round was a Series B financing.
Why did they raise?
Isomorphic Labs raised to scale IsoDDE, expand AI and drug-design teams, and advance internal and partnered programs toward clinical trials.
Fathom Therapeutics raised $47M in Series A funding in April 2026
When was it?
The deal was announced on 27 April 2026.
Who are they?
Fathom Therapeutics, formerly Atommap, uses quantum chemistry and AI to predict how drug molecules behave inside living cells.
Geographical focus?
Fathom Therapeutics is US-focused, with operations in New York and Boston.
Why do we include them in the AI in drug discovery market?
Fathom Therapeutics fits because its platform supports AI-enabled small-molecule design and lead optimization before human trials.
What is the company stage?
Fathom Therapeutics is an early-growth, preclinical platform-stage company.
How much did they raise?
Fathom Therapeutics raised $47M in this round.
What round is it?
The round was a Series A financing.
Why did they raise?
Fathom Therapeutics raised to scale its computational drug-design platform, expand lab-in-the-loop validation, and advance internal programs.
This chart, featured in our AI in drug discovery market deck, shows how Shrödinger is positioned in AI drug discovery
10x Science raised $4.8M in seed funding in April 2026
When was it?
The deal was announced on 22 April 2026.
Who are they?
10x Science builds AI-native software for molecular-level protein characterization and biologics candidate assessment.
Geographical focus?
10x Science is based in the San Francisco Bay Area and serves global biopharma teams.
Why do we include them in the AI in drug discovery market?
10x Science fits because its platform helps drug developers decide which protein therapeutics should advance before human trials.
What is the company stage?
10x Science is moving from MVP to early product-market fit, with Stanford-linked roots and Y Combinator W26 backing.
How much did they raise?
10x Science raised $4.8M in this round.
What round is it?
The round was a seed financing.
Why did they raise?
10x Science raised to build the foundational AI layer for protein characterization and support pharma and biotech adoption.
Helical raised $10M in seed funding in April 2026
When was it?
The deal was announced on 14 April 2026.
Who are they?
Helical builds a virtual AI lab that turns biological foundation models into reproducible in-silico drug discovery workflows.
Geographical focus?
Helical is based in the UK and Europe, with global pharma customers.
Why do we include them in the AI in drug discovery market?
Helical fits because its AI foundation-model infrastructure supports target discovery, biomarker discovery, and therapeutic design workflows.
What is the company stage?
Helical is an early product-market-fit company with pharma traction, including top-20 pharma users.
How much did they raise?
Helical raised $10M in this round.
What round is it?
The round was a seed financing.
Why did they raise?
Helical raised to scale its virtual lab, expand pharma programs, and make in-silico discovery reproducible at pharma scale.
In our AI in drug discovery market deck, we identify pain points entrepreneurs should prioritize
DeepCyte raised $1.5M in seed funding in April 2026
When was it?
The deal was announced on 9 April 2026.
Who are they?
DeepCyte develops single-cell AI toxicology tools that detect, predict, and explain drug-induced toxicity before patients are exposed.
Geographical focus?
DeepCyte has a US-Danish footprint and targets global biopharma customers.
Why do we include them in the AI in drug discovery market?
DeepCyte fits because its platform supports preclinical ADMET and toxicity prediction for candidate de-risking.
What is the company stage?
DeepCyte is at launch and MVP stage, with products called MetaCore and DeeImmuno.
How much did they raise?
DeepCyte raised $1.5M in this round.
What round is it?
The round was a seed financing.
Why did they raise?
DeepCyte raised to launch and advance its single-cell AI toxicology platform for drug development.
Generare raised about $23M in Series A funding in April 2026
When was it?
The deal was announced on 2 April 2026.
Who are they?
Generare uses AI to decode microbial genomes and generate novel molecular data for discovering new drug-like compounds.
Geographical focus?
Generare is based in Paris and serves global drug-development customers.
Why do we include them in the AI in drug discovery market?
Generare fits because its AI-enabled genomic mining platform supports hit generation and novel molecule discovery.
What is the company stage?
Generare is an early-growth platform-stage company scaling a proprietary discovery library.
How much did they raise?
Generare raised about $23M in this round.
What round is it?
The round was a Series A financing.
Why did they raise?
Generare raised to expand its compound library, grow the team, and scale the molecular discovery platform.
This market map, featured in our AI in drug discovery market deck, highlights top companies and startups in the AI in drug discovery market
RyboDyn raised $10M in seed funding in March 2026
When was it?
The deal was announced on 24 March 2026.
Who are they?
RyboDyn uses AI and high-resolution sequencing to decode the dark proteome and identify hidden cancer targets.
Geographical focus?
RyboDyn is based in San Diego and focuses on oncology target discovery with global relevance.
Why do we include them in the AI in drug discovery market?
RyboDyn fits because its platform supports AI target discovery and target validation before therapeutic development.
What is the company stage?
RyboDyn is moving from MVP and early platform scale toward IND-enabling work.
How much did they raise?
RyboDyn raised $10M in this initial close.
What round is it?
The round was a seed initial close.
Why did they raise?
RyboDyn raised to scale RyboCypher and CypherAtlas and move early oncology programs toward IND-enabling studies.
Ternary Therapeutics raised about $4.5M in seed funding in March 2026
When was it?
The deal was announced on 16 March 2026.
Who are they?
Ternary Therapeutics uses machine learning, molecular modeling, and lab feedback to design molecular-glue drugs.
Geographical focus?
Ternary Therapeutics is London-based, with lab space at Stevenage Bioscience Catalyst.
Why do we include them in the AI in drug discovery market?
Ternary Therapeutics fits because its AI platform designs molecular-glue therapeutic candidates before trials.
What is the company stage?
Ternary Therapeutics is a preclinical platform and MVP-stage company.
How much did they raise?
Ternary Therapeutics raised about $4.5M in this round.
What round is it?
The round was a seed financing.
Why did they raise?
Ternary Therapeutics raised to scale its AI platform, expand biology and chemistry capabilities, and make molecular-glue discovery more systematic.
This chart, featured in our AI in drug discovery market deck, shows annual funding in AI drug discovery startups
Antiverse raised $9.3M in Series A funding in March 2026
When was it?
The deal was announced on 3 March 2026.
Who are they?
Antiverse designs therapeutic antibodies for difficult targets such as GPCRs and ion channels using AI and in-house lab validation.
Geographical focus?
Antiverse is headquartered in Cardiff, with offices in Boston and Prague.
Why do we include them in the AI in drug discovery market?
Antiverse fits because its platform supports AI antibody design and biologics lead generation before human trials.
What is the company stage?
Antiverse is at product-market-fit and preclinical program stage, with partner work and internal lead programs.
How much did they raise?
Antiverse raised $9.3M in this round.
What round is it?
The round was a Series A financing.
Why did they raise?
Antiverse raised to accelerate internal antibody programs toward in-vivo efficacy studies and expand partner programs.
Tamarind Bio raised $13.6M in Series A and additional funding in February 2026
When was it?
The deal was announced on 26 February 2026.
Who are they?
Tamarind Bio provides no-code infrastructure for life-science teams to run molecular AI and simulation models.
Geographical focus?
Tamarind Bio is based in San Francisco and serves biotech and pharma users globally.
Why do we include them in the AI in drug discovery market?
Tamarind Bio fits because its platform enables molecular AI models for discovery workflows and preclinical decision-making.
What is the company stage?
Tamarind Bio is at product-market-fit to early-growth stage, with adoption across roughly 100 biotech organizations.
How much did they raise?
Tamarind Bio raised $13.6M in total, including a $12M Series A.
What round is it?
The round was a Series A plus additional funding.
Why did they raise?
Tamarind Bio raised to build core infrastructure for AI-powered drug discovery inference and make molecular AI usable by bench scientists.
Related blog posts
- How strong is fundraising in the AI in drug discovery market right now?
- The latest news in AI for drug discovery
- How large is the AI in drug discovery market in reality?
- The evolution of funding activity in AI for drug discovery
- The main fundraising trends in AI for drug discovery
- All funding deals in AI for drug discovery
- Which companies have raised the most funding in AI for drug discovery?
- Which companies are the most valued in AI for drug discovery?
- A complete list of business models in AI for drug discovery
